About T3D Therapeutics
T3D Therapeutics is a company based in Durham (United States) founded in 2013 by John Didsbury. T3D Therapeutics has raised $33.02 million across 15 funding rounds from investors including HHS, NCBiotech and National Institute on Aging. T3D Therapeutics offers products and services including T3D-959. T3D Therapeutics operates in a competitive market with competitors including Alzheon, Longeveron, Shaperon, Alchemab and Eikonizo, among others.
- Headquarter Durham, United States
- Founders John Didsbury
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name T3d Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$33.02 M (USD)
in 15 rounds
-
Latest Funding Round
$2.26 M (USD), Grant
Aug 15, 2023
-
Investors
HHS
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of T3D Therapeutics
T3D Therapeutics offers a comprehensive portfolio of products and services, including T3D-959.
Targets brain metabolism to treat Alzheimer's and improve cognitive function.
People of T3D Therapeutics
Unlock access to complete
Unlock access to complete
Advisor Team
8 people
Leadership Team
8 people
Product Management Team
1 people
Consultant Team
1 people
Unlock access to complete
Funding Insights of T3D Therapeutics
T3D Therapeutics has successfully raised a total of $33.02M across 15 strategic funding rounds. The most recent funding activity was a Grant round of $2.26 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in T3D Therapeutics
T3D Therapeutics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, NCBiotech and National Institute on Aging.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech startups are incubated and funded in North Carolina.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Research and information on aging are provided by this institute.
|
Locked | Locked | Locked |
Investor details for T3D Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by T3D Therapeutics
Investment portfolio details for T3D Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - T3D Therapeutics
Detailed financials for T3D Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
T3d Therapeutics Comparisons
Peer comparison for T3D Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of T3D Therapeutics
T3D Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alzheon, Longeveron, Shaperon, Alchemab and Eikonizo, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Oral inhibitors of amyloid aggregation for Alzheimer's treatment are developed.
|
|
| Locked | Locked | Locked |
Cellular therapies for aging-related and life-threatening conditions are developed.
|
|
| Locked | Locked | Locked |
Therapies for inflammatory diseases and cancer are developed.
|
|
| Locked | Locked | Locked |
Developer of antibody based therapeutics to treat cancers, neurodegenerative conditions and infectious diseases
|
|
| Locked | Locked | Locked |
Brain-penetrant small molecule therapeutics for neurodegenerative diseases are developed.
|
Detailed competitors of T3D Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on T3d Therapeutics
Complete news archive for T3D Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about T3D Therapeutics
T3D Therapeutics was founded in 2013.
T3D Therapeutics is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
John Didsbury is the current CEO of T3D Therapeutics. They have also founded this company.
T3D Therapeutics is a funded company, having raised a total of $33.02M across 15 funding rounds to date.
T3D Therapeutics was founded in 2013 and is based in Durham, United States. Operations focus on the biotechnology sector, with emphasis on creating treatments for neurodegenerative conditions. A key product, T3D-959, is designed to address multiple Alzheimers disease pathologies, such as beta-amyloid and tau pathways, along with insulin and IGF-resistance mechanisms. Development efforts target core disease triggers in this field.
T3D Therapeutics's top competitors include Alzheon, Longeveron and Alchemab.
T3D Therapeutics offers T3D-959.
T3D Therapeutics has 3 investors. Key investors include HHS, NCBiotech, and National Institute on Aging.